List of Diagnostics Companies in United Kingdom - 62

We are lateral flow CDMO experts based in the UK supporting global customers bring their assays to market, from proof of concept, through optimisation and scale up to routine manufacture, along with full-service regulatory consultancy support. Get in touch: email info@abingdonhealth.com today. We believe that by developing the high quality, effective lateral flow rapid tests combined with our manufacturing experience and scale, we can provide the means to accelerate access to rapid testing. This means faster diagnosis and screening in the field, accelerating the ability of decision makers to deploy a more rapid response to results. We are committed and honest in all that we do. We value the quality and contribution of all, priding ourselves on building long-lasting and trusting partnerships – because by working transparently with customers, partners and colleagues, we are better together. With an exceptional pedigree in developing and manufacturing rapid tests Abingdon Health are expert in responding to our customers varied needs with specific and customisable solutions. Our mission: To improve life by making rapid results accessible to all. By providing the best lateral flow rapid test solutions, we believe we can support the increase in access to diagnostics across many industries and locations throughout the world. Faster access to results allows for rapid decision making and solutions. This ability has a significant role to play in improving life in so many ways.

AgeCurve Limited is a company that offers tools to measure scalable single cell somatic mutation burden across the life sciences market space. They also provide a deep age profiling kit intended to calculate comprehensive biological aging patterns in a saliva sample.

Formed in late 2017, AMLo Biosciences is dedicated to providing a prognostic test for early AJCC Stage I and Stage II melanoma to better identify patients' true risk of disease progression. Those patients who are genuinely at low-risk of disease spread can be provided reassurance and better-informed follow-up care, while those identified at risk of metastasis are enabled to receive timely treatment. The test under development – AMBLor® – will be simple to use and fits seamlessly into current diagnostic practice. AMLo Biosciences has been founded by a team with an internationally acclaimed research track record in the melanoma field, through identification of translational biomarkers, drug discovery & development and the building of biotech companies.

AMPED PCR Ltd is a biotech startup based in Bethania, North Wales. The company manufactures PCR reagents that outperform industry gold standards while costing a fraction of the price. They provide molecular diagnostics solutions for researchers in Life Sciences and Applied Markets.

ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. ANGLE’s commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system and associated consumables. The clinical services business is offered through ANGLE’s GCP-compliant laboratories in the UK and the United States. Services include custom made assay development and clinical trial testing for the pharmaceutical industry. Over 80 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com

APIS is leveraging systems biology, interrogating multi-OMICs biodata, and deploying innovative ‘Clickmer’ ligand binding technology, for the validation and translation of biomarker and therapeutic assets into clinical utility. APIS has deep expertise and capabilities in IVD development of molecular & immune assays for ultimate product realisation as diagnostic tests. In addition, APIS' expertise in bioinformatics and software development is offered as an agile service to our clients, to develop bespoke, end-to-end multi-OMICs solutions and platform development. APIS has also developed a broad breast oncology product portfolio: The APIS Breast Cancer Subtyping Kit is a reproducible RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. The APIS ESR1 Mutations Kit is a qPCR assay for the sensitive detection of eleven key mutations within the oestrogen receptor gene. Coming soon - the new APIS PIK3CA Mutations Kit is a qPCR assay for the sensitive detection of key mutations in the PIK3CA gene.

APS Biocontrol Ltd. (APS) develops biocontrol solutions for the management of bacterial diseases and other microbial contaminants in agriculture and food processing, where concerns regarding the use of synthetic chemicals have resulted in a programme of withdrawals that will have a dramatic impact on the ability of (a) growers to achieve commercial yields and quality and (b) suppliers to ensure the quality of post-harvest packed produce. APS' patented Biolyse technology (based on naturally-occurring antimicrobials; bacteriophage) provides safe, effective and environmentally-sustainable replacements. If you have a problem with bacterial breakdown or contamination, in any sector, our Biolyse technology could be an effective solution. APS is also the company behind Scotland's favourite insect repellent, Smidge (further details can be found at www.smidgeup.com)

Axis Shield is a company that specializes in the development and manufacture of in vitro diagnostic tests, focusing on proprietary markers for early diagnosis and management of critical illnesses like cardiovascular and neurodegenerative diseases.

At Biofortuna we form unique partnerships with the most innovative healthcare and life science companies and work together to enhance health and wellbeing all over the world. Our services are wide-ranging, and whether we are supporting diagnostic companies, food safety experts or life science specialists our objectives are the same; to form long term partnerships and become a valued extension of your team. We do that by solving problems and presenting opportunities. We listen to your requirements, develop customised solutions and deliver them with openness and transparency. Operating from state-of-the art, purpose built premises, and benefiting from ISO 13485 certification, ISO 17025 accreditation and FDA registration, we have a proven track record in the development and large-scale manufacture of PCR and LAMP molecular assays and immunoassays.

Biosceptre is developing a multi-targeted universal CAR-T system, designed to incorporate our nfP2X7 technology, to be capable of treating a range of cancers.

Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is a growing international molecular imaging company focused on delivering innovative, well-differentiated diagnostic solutions that inform patient care. Formed in 2014, the Company’s success is driven by its management expertise and supported by a demonstrated track record of rapid development and commercialization of positron emission tomography (PET) radiopharmaceuticals. With a clinical focus in cancer, Blue Earth Diagnostics’ expanding pipeline encompasses a variety of disease states, including prostate cancer and neuro-oncology. Blue Earth Diagnostics is committed to the timely development and commercialization of precision radiopharmaceuticals for potential use in imaging and therapy.

We turn ordinary scans into extraordinary insights because every patient deserves expert-level care, anywhere. Impactful. Scalable. Smart. Brainomix 360 enhances stroke imaging interpretation for neurologists, interventionalists, and radiologists while seamlessly fitting into existing radiology workflows. Delivering the right insights, to the right people, at the right time. Since our 2010 spin-out from the University of Oxford, we've developed award-winning, AI-powered imaging biomarkers and software solutions that empower physicians worldwide to make critical, life-saving decisions in stroke and lung care.

Carcinotech provides comprehensive solid tumour research services to therapeutic developers and healthcare professionals. At the heart of its offerings is the proprietary Carcino3D™ bioprinting platform, which creates assay-ready, 3D tumours from patient biopsies. Unlike conventional cancer models, Carcinotech’s bioprinted constructs incorporate multiple cell types—including immune cell populations—within a robust tissue matrix, offering a more biologically relevant and controlled model for early drug discovery, preclinical and co-clinical studies, and personalised treatment testing.

Caristo Diagnostics has been formed to bring revolutionary cardiovascular diagnostic tools to patients worldwide. Our proprietary technology transforms the accuracy of routine cardiac CT scans by extracting new information that is otherwise invisible, greatly enhancing the power to predict cardiovascular risk and refine treatment decisions. Our Website: https://www.caristo.com Follow us on Twitter: https://twitter.com/CaristoHeart

Carta provides advanced genomic testing for IVF. We help IVF parents predict their embryo's disease risk and health outcomes in advance, resulting in improved women's health and healthier babies.

Cellsway is a fresh deep-tech start-up founded in March 2020 in UK to convert the know-how and cutting-edge core technology that have been developed and cultivated at Mikro Biyosistemler Inc. into commercial products to set the gold standard for diagnosis and management of cancer. The flagship product of the company is a liquid biopsy platform which uses a simple blood sample for cancer diagnostics and cancer research. The patent-pending microfluidic technology enables isolation and enumeration of Circulating Tumor Cells (CTCs) from the blood samples of cancer patients.

Cirdan designs, manufactures and supplies innovative software and imaging solutions for the acceleration and enhancement of diagnosis. Our systems are optimised for pathology and clinical laboratory usage. Cirdan's primary product is its world-class Laboratory Information System, ULTRA. ULTRA has been designed to streamline laboratory operations and is currently installed in more than 72 laboratories across 6 continents. Another core product is PathLite Compact, a purpose-built system designed specifically for gross imaging within clinical laboratories. The company was founded in 2010 and is headquartered in Lisburn, Northern Ireland and has additional offices in Canada and Australia. Cirdan is also responsible for organising Pathology Horizons, an annual and open CPD conference on the future of pathology. For more information visit - www.pathologyhorizons.com

Starting with a vision to truly take paternity testing to the general public, Complement Genomics has been bringing forward new DNA testing services since 2000. Working in areas as diverse as clinical trials and non-human DNA testing, the highly trusted company has considerable expertise in pharmacogenetics. Complement Genomics also provides COVID-19 testing for private clients and businesses. Operating from the Durham Genome Centre, Complement Genomics has developed different brands according to the market segment: - dadcheck®gold - DNA testing services for professionals, including solicitors, barristers, local authorities and social services - dadcheck®silver - a full range of DNA testing services for the general public, including paternity and other human relationships, for the determination of parentage, for immigration DNA tests or for DNA tests which are suitable for other legal purposes - Chxout - services designed to serve the non-human DNA testing market – for citizen scientists and professionals alike. Bat Species Identification | Bird Sexing | Bird Species Identification | Bird Parentage | DNA Barcoding of animals, plants and fungi - Geneblitz - designed to serve the CRO and pharmaceutical sector with genotyping and phenotyping for clinical trials - That DNA Company - an online value brand providing DNA testing services, primarily paternity tests, for the general public

Cumulus Neuroscience is a global digital health company focused on advancing neuroscience clinical trials and research. They collaborate with leading global pharmaceutical companies to meet the industry's complex clinical trial needs. Cumulus Neuroscience offers a unique career and is known for its innovative assessment platform for identifying brain disorders.

DiagNodus is a biomedical research services company that specializes in pathology and molecular biology, offering laboratory-based projects, research design, clinical trial services, and sample analysis.

DNAe is commercializing its pioneering semiconductor sequencing technology for healthcare applications where rapid point-of-need diagnostics are of critical need, including infectious disease and cancer testing and monitoring. It is developing the LiDia-SEQ™ system, a user-friendly, direct-from-specimen platform that performs genomic analysis on a microchip, to provide comprehensive, actionable information to clinicians in a matter of hours, versus days. DNAe’s initial focus is on infectious disease diagnostics, starting with a groundbreaking test for bloodstream infections (BSI) and antimicrobial resistance (AMR), which uses whole blood specimens to directly detect and identify infections that lead to sepsis. This will provide clinicians with actionable information to help select the appropriate antibiotics to treat the disease. A pipeline of follow-on tests is in development for viruses and cancer testing and monitoring. DNAe has received “Breakthrough Device” designation from the US Food and Drug Administration (FDA) for its pioneering platform and first assay. Headquartered in London, UK, DNAe has expanded operations further in with a clinical diagnostic development and manufacturing site in San Diego, CA. We are always on the lookout for exceptional talent. For more details, visit www.dnae.com. Or get in touch, we would love to hear from you. Twitter: @dna_electronics Instagram: dna.electronics

Dxcover is a clinical stage liquid biopsy company developing tests for the early detection of multiple cancers, when treatment has a better chance to impact outcomes. The company has pioneered the early detection and identification of cancer employing infrared spectroscopy of circulating pan-omic biomarkers. The company has generated compelling clinical data with high accuracy detection of Stage I and Stage II cancers. Dxcover is based in Scotland, United Kingdom and is establishing operations in the USA.

EKF is a leading global diagnostics and biotechnology company specialising in the development, production, and distribution of leading medical technologies and patient-centric solutions. Our diagnostic technologies and biotechnology solutions empower healthcare professionals and non-medical practitioners to make informed decisions through point-of-care testing and life sciences applications. Point-of-Care: EKF develops and manufactures medical devices and tests (in-vitro diagnostics (IVD)) that can be used at or near the patient's location. Designed to provide quick and accurate results, these tests (and optional data connectivity software) enable healthcare professionals to make rapid decisions. Diabetes care: EKF offers a range of products related to diabetes care, including glucose monitoring systems and associated supplies and consumables. Hematology solutions: EKF provides products, supplies, and consumables for measuring hemoglobin levels, including those used for the detection of hemoglobin variants. Life Sciences: EKF develops and supplies diagnostic and therapeutic enzymes, proteins, reagents, and other bio-materials used in the research, biotechnology, and pharmaceutical industries. Dedicated to supporting clinicians, scientists and researchers these high-quality materials can be used in multiple applications. Enzyme Fermentation: EKF offers precision fermentation, custom bioprocessing and contract manufacturing services related to the production of pharmaceuticals and other biologics. Beta-hydroxybutyrate (β-HB): EKF provides β-HB products which are used to detect ketones, to help identify patients suffering from diabetic ketoacidosis, and other clinical applications. As a global leader in the development and distribution of diagnostic technologies and biotechnology solutions, EKF has a presence in over 120 countries with the solutions needed to support better health and wellness worldwide.

Yourgene Health is a leading integrated technologies and services business, enabling the delivery of genomic medicine. Yourgene works in partnership with global leaders in DNA technology to advance diagnostic science. Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and infectious diseases. Flagship in vitro diagnostic products include Non-Invasive Prenatal Tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping. Yourgene has a range of innovative DNA sample preparation platforms, powered by Ranger® Technology, the LightBench® and the LightBench® Detect instruments are ideal for cell-free DNA applications in NIPT, gene synthesis and oncology, including liquid biopsy. Yourgene Genomic Services is a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. Yourgene Health is headquartered in Manchester, UK with facilities in Singapore, the US and Canada. Yourgene is now part of the Novacyt group of companies. For more information visit www.yourgenehealth.com

Enigma Diagnostics is a PCR-based testing out of the laboratory with a range of simple-to-use products.

Neurodegenerative disorders present a huge societal burden, and one from which few of us remain untouched in some way. Unfortunately, by the time a diagnosis is made, it is often too late and irreversible damage is already done. It is essential that patients get examined as early as possible, and that symptoms get diagnosed accurately. This allows the right patients to receive the right treatments at the right time, to help to slow progression, and mitigate symptoms. Pharma and Biotech companies that are developing disease modifying therapies also have a need for biomarkers for neurodegenerative disorders that can help predict disease presence, monitor disease progression and treatment response. ESP Diagnostics is developing scalable liquid-biopsy tests based upon measurements of specific neurodegenerative disease biomarkers in extracellular vesicles (EVs) extracted from blood, saliva and urine. The ESP biomarker tests will allow early pre-symptomatic detection of neurological disorders such as Parkinson’s Disease, Dementia with Lewy Bodies, and a differential diagnosis of Alzheimer’s. We provide assay services to pharma and biotech companies developing disease-modifying therapies (stratification, disease progression, surrogate endpoints, reverse translation, target engagement), and are developing IVD products for patients, clinicians and healthcare providers worldwide.

A Social Enterprise which is applying for B Corporation status. The first fully automated sample-to-result platform. Launching in late 2023 with a respiratory assay to simultaneously detect flu A, flu B, RSV A, RSV B and Covid-19. Low cost testing with no CapEx as the platform is lent. Rugged and mobile it can be used where and when it is most need at infection hotspots.

genedrive plc is a molecular diagnostics company developing and commercialising a low-cost, rapid, versatile, simple to use and robust point of need molecular platform for use in patient stratification (genotyping). We are passionate about the opportunity to build a sustainable business around molecular diagnostics and to play an important role in the diagnostic and treatment challenges presented by global health issues. The company launched the Genedrive MT-RNR1 ID Kit, a pharmacogenetic test to prevent antibiotic induced deafness in infants, which was co-developed with the partners in the UK's National Health Service and is now used for routine clinical use.

We are a molecular diagnostics company working predominantly in the fields of infectious disease, cancer diagnostics and personalised medicine. Our ethos is to offer robust easy-to-use, sensitive, and affordable molecular diagnostics technologies and products to researchers, clinicians and drug companies to enable accurate diagnosis and the delivery of safe and effective medicines. Our patented technologies allow for simultaneous detection of multiple targets in one reaction. If you have a project or collaboration in mind, we'd love to hear from you! Do you have a requirement for detecting multiple targets? Are you working with bacteria, viruses or fungus? We can help you achieve what you need with our dedicated team of experts. Drop us a line here or email us at info@genefirst.com

GENinCode specializes in risk assessment and prediction of cardiovascular disease , thrombosis and familial hypercholesterolemia . Cardiovascular disease (CVD) is a broad disease classification including coronary artery disease such as angina and myocardial infarction often referred to as heart attack. CVD also includes stroke, heart failure, hypertension and other vascular heart diseases and is the leading cause of death and disability worldwide accounting for 1 in every 4 deaths in the United States. GENinCode provides advanced genomic technology, products and recommendations fully validated by our scientific and clinical team. Our goal is to provide doctors and health care practitioners with advanced health information that combines both traditional clinical measures with a patient's genetic information to provide a comprehensive risk assessment and clinical recommendation to help decision-making. Our technology helps select the optimal treatment pathway and informs and educates patients to become more aware of their cardiovascular risk helping patient adherence and empowerment to better manage their health. GENinCode technology and advanced genomic products provide information that helps patients and healthcare practitioners to assess and predict the onset of cardiovascular disease, thrombosis, and the diagnosis of Familial Hypercholesterolemia. Our online reporting system SITAB® helps inform doctors of their patients' health risk enabling patient behavioral and lifestyle changes alongside delivering the most effective therapies and treatment pathways.

GENinCode specializes in risk assessment and prediction of cardiovascular disease , thrombosis and familial hypercholesterolemia . Cardiovascular disease (CVD) is a broad disease classification including coronary artery disease such as angina and myocardial infarction often referred to as heart attack. CVD also includes stroke, heart failure, hypertension and other vascular heart diseases and is the leading cause of death and disability worldwide accounting for 1 in every 4 deaths in the United States. GENinCode provides advanced genomic technology, products and recommendations fully validated by our scientific and clinical team. Our goal is to provide doctors and health care practitioners with advanced health information that combines both traditional clinical measures with a patient’s genetic information to provide a comprehensive risk assessment and clinical recommendation to help decision-making. Our technology helps select the optimal treatment pathway and informs and educates patients to become more aware of their cardiovascular risk helping patient adherence and empowerment to better manage their health. GENinCode technology and advanced genomic products provide information that helps patients and healthcare practitioners to assess and predict the onset of cardiovascular disease, thrombosis, and the diagnosis of Familial Hypercholesterolemia. Our online reporting system SITAB® helps inform doctors of their patients’ health risk enabling patient behavioral and lifestyle changes alongside delivering the most effective therapies and treatment pathways.

GenomeKey enables targeted Sepsis treatment in hours, rather than days. This is important because Sepsis now kills more people than cancer. It can hit anyone, of any age, and kills within hours. A patient admitted to a hospital today, they wait 3 days before the doctor knows which antibiotic will fight the infection. We use cutting edge machine learning and DNA sequencing to bring 3 days down to just a few hours, with the only affordable test that provides a result for every patient. This saves lives, saves money, and saves our last antibiotics for when we really need them.

InvenireX is a biotechnology company developing real-time, ultra-sensitive Nucleic-acid detection instrumentation powered by the latest AI neural networks.

LEX Diagnostics is a privately held molecular diagnostics company developing products designed to enhance patient care by delivering clinical insights within minutes and at the time they are most valuable. Delivering a high-speed molecular test will redefine point-of-care diagnostics.

Linear Diagnostics Limited (LDL) is a diagnostics company based on a novel technology that allows wide range of molecular diagnostics tests to be carried out using a simple optical system. The technology provides significant advantages over the current state of the art allowing a more rapid detection of multiple targets using a single simple reagent. Such a solution has applications in a number of high-value sectors including health, food, defence and security. LDL has also established development partnerships with a number of end users including clinical microbiology, food producers and defence medicine.

We are a team based in London, that develops a platform to help assess people with Parkinson's disease better. Motor assessment in Parkinson's disease is plagued by issues of subjectivity and reproducibility – not to mention systematic biases such as rater drift. To counter this, we are developing a platform, called Kelvin, that can be used from any device (e.g. smartphones or tablets). Named after the famous physicist so beloved of precise measurement, the platform allows researchers to record, score, store and analyse video of Parkinson's patients during motor assessment. Once captured and organised, the platform uses a cutting-edge computer vision technique, called pose estimation, to objectively track the movement of the patients down to the fingertip level and deliver objective metrics of core symptoms, such as tremor and bradykinesia.

Microbiotica identifies gut bacteria linked to phenotype with unprecedented precision in order to discover and develop live bacterial therapeutics and biomarkers

Microplate Dx Limited specialises in rapid antibiotic susceptibility testing diagnostics, enabling clinicians, at the point-of-care, to confidently select the best choice of antibiotic to treat a patient's infection in a matter of minutes, significantly quicker than the current gold standard technology which takes at least 2 days. Our award-wining, platform diagnostic test helps reduce the major global health threat of antimicrobial resistance and ultimately, saves lives.

‘Neuro-Bio has discovered a novel 14 amino acid bioactive peptide (T14) derived from the C terminus of AChE. T14 is neurotoxic in the adult brain and published data shows it to be a potential key driver of neurodegeneration. This new distinct mechanism is being exploited by Neuro-Bio to discover first-in-class drugs to treat Alzheimer's disease and to develop a biomarker as a companion diagnostic'.

Low-cost, rapid whole genome sequencing is the future of infection control and clinical microbiology. Next Gen Diagnostics offers the low cost, high throughput, and automated sequencing and bioinformatics for a range of application, including tracking the transmission of disease in hospitals and pathogen surveillance for public health labs.

Oncimmune is a leading immuno diagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Our growing range of diagnostic products can detect early-stage cancer and our service-based platform, delivers actionable insights into therapies to our pharmaceutical and biotech partners. Oncimmune's ImmunoINSIGHTS platform enables life-science organisations to optimise drug development and delivery, leading to more effective targeted as well as safer treatments for patients. Oncimmune is headquartered in the UK, with a discovery research centre in Dortmund, Germany and an office in Cambridge MA, USA.

When a five-year-old boy was blinded after a regular eye exam failed to spot a retinal detachment, his father made it his life's work to help eye care professionals by revolutionising retinal imaging. Optos was founded by Douglas Anderson with the goal to make a patient-friendly device to capture a digital ultra-widefield image of the retina. Today, millions of patients around the world have benefited from optomap® retinal imaging. You will find optomap systems in many independent High Street optometrists, as well as eye clinics at Great Ormond Street Hospital in London and Harvard Medical Center in Massachusetts. Our core products produce high resolution optomap images of 82% or 200◦ of the retina, something no other imaging device is capable of in a single comfortable capture. The most recent innovation from Optos integrates ultra-widefield retinal imaging and image-guided Optical Coherence Tomography (OCT). This combined device facilitates the early detection, management and effective treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy, and age-related macular degeneration. More than 1,000 published and ongoing clinical trials as well as thousands of case studies and testimonials show the long-term value of optomap imaging and OCT in diagnosis, treatment planning, and patient engagement. As a division of Nikon Co. Ltd, Japan since 2015, Optos is approaching its 30th anniversary and proud to be recognized as a leading provider of devices to eye care professionals to provide a more complete approach to patient care.

Osler is a UK-based diagnostics company whose purpose is to enable anyone, anywhere, to access, understand, and act on their health, to live healthier, happier, and longer lives. Osler has developed the Osler Origin – a 'portable lab' that can provide lab-quality diagnostics to anyone, anywhere, at any time. The Osler Origin will offer a wide portfolio of diagnostic tests and serve all major healthcare settings, globally. Osler was formed out of the University of Oxford in 2017, following decades of research from the same department that invented the portable electrochemical blood glucose sensor. The Company is headquartered in Oxford, UK.

Owlstone Medical is developing a breathalyzer for disease. With a goal of finding ways to improve non-invasive diagnostics for respiratory diseases, liver diseases, cancer, digestive health, and other conditions. Our mission is to save 100,000 lives and $1.5B in healthcare costs by advancing early detection and precision medicine. Breath Biopsy® aims to develop a new diagnostic modality making it possible to discover novel non-invasive biomarkers in breath using a platform with the potential to transition to point-of-care. The award-winning ReCIVA® Breath Sampler ensures the reliable collection of breath samples. The volatile organic compounds (VOCs) present in breath are analyzed using state-of-the-art chemical analysis technologies. Our aim is to develop tools, potentially based on our proven microchip chemical sensor technology (FAIMS), to detect validated biomarkers of disease. The Breath Biopsy platform provides biomarker discovery and validation capabilities to support the development of applications in precision medicine for a wide range of other medical conditions. Highly sensitive and selective, our platform allows for early diagnosis when treatments are more effective and more lives can be saved. Owlstone Medical is involved in studies related to major and rapidly growing health concerns including lung cancer, asthma and liver disease. We are also participants in extensive partnerships focusing on multiple cancer types, pulmonary hypertension, mesothelioma, workplace exposures and much more. Our Breath Biopsy Products and Services are available to academic, clinical, and pharma research partners who want to develop breath-based diagnostics for their own applications. Our products and services are for research use only. Not for use in diagnostic procedures.

Oxford BioDynamics (OBD) is a global biotech company advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. OBD aims to help people face the most challenging health decisions with confidence and tackle the rising costs of healthcare with a portfolio of clinical tests and research tools based on its proprietary EpiSwitch® technology, uniquely capable of reproducibly translating 3D genome regulation for clinical application. The company's flagship product, EpiSwitch CiRT (Checkpoint inhibitor Response Test), is a first-of-its-kind smart blood test for cancer patients that provides guidance on navigating the toughest challenges of immunotherapy like treatment planning, pseudo-progression, and adverse events. The company is partnering with CLIA-certified commercial labs to deliver these important tests into the hands of physicians to meet demand and help patients as quickly as possible. OBD's 24,000 sq ft headquarters in Oxford, UK, houses offices and state-of-the-art laboratory facilities. OBD's commercial team has an office in Gaithersburg, MD, USA, and the company has an ISO-certified laboratory in Penang, Malaysia. OBD has participated in 40+ partnerships with pharma and leading institutions, including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital, and Mitsubishi Tanabe Pharma. The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostics, bioinformatic tools for 3D genomics, and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from 10,000+ samples in 30+ human diseases. OBD's proprietary EpiSwitch technology maps this 3D architecture at scale, identifying abnormal configurations that can be used to diagnose patients or predict how someone may respond to a disease or treatment. For more information, please visit oxfordbiodynamics.com.

Oxford Brain Diagnostics Ltd is rethinking how brain health is assessed and managed. Founded in neuropathological and neuroimaging expertise, the company's patented Cortical Disarray Measurement (CDM®) technology uses MRI brain scan data to support early and differential diagnosis, track progression, and predict the decline of neurodegenerative diseases. Oxford Brain Diagnostics is committed to assessing brain health based on changes in the cellular structure, supporting drug development, and helping clinicians around the world in their fight to defeat Alzheimer's and other neurodegenerative diseases.

Oxford Cancer Analytics Ltd (OXcan) is on a mission to enable curative cancer treatments through early detection. OXcan's machine learning platform enables minimally invasive and inexpensive cancer screening in high risk populations through analysing cancer materials shed into the blood. OXcan hopes to create a paradigm shift in screening and eventually replacing invasive tissue biopsy and expensive, complex imaging as the current standard of care. It is safer, cheaper, and detects cancers much earlier, when they are still curable.

Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world's first and only nanopore DNA and RNA sequencing platform. It's a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society. Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide. Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.

Perspectum's imaging solutions are safe, fast, and can offer more comprehensive diagnostics. We help doctors understand complex data and help deliver precision care to more patients. We believe the voice of the patient matters and that each case is unique. Our goal is to enable health care providers to tailor precision medicine to the needs of the individual.

PlaqueTec is pursuing a better understanding of the biological mechanisms of coronary artery disease (CAD) to advance the development of precision medicine. CAD, where atherosclerotic plaque build-up narrows or blocks the arteries that supply blood to the heart, is a leading cause of death globally. Current treatment approaches are one-size-fits-all and therefore ineffective for many patients. To address this, PlaqueTec has developed a proprietary technology and data analysis platform to endotype patients and uncover potential biomarkers of coronary vascular function and plaque progression. A more detailed understanding of patient endotypes will support drug development by identifying new targets in specific patient groups, reducing clinical trial sizes and costs, and increasing success rates, ultimately improving outcomes for patients.

ProteinLogic has developed ImmiPrint®, a novel diagnostic technology platform, based on the detection of non-obvious diagnostic patterns in soluble immune proteins in the blood and other body fluids through machine learning.

We profile the fundamental building blocks of life, providing cross-sectional snapshots, like a CT scan for your blood. We want to impact both primary and secondary care pathways. Our mission is to light the way in which cancer is diagnosed, treated and monitored. We aspire to deploy at population-level within the UK and globally.

PulmoBioMed commercialises state-of-the-art exhaled breath condensate & aerosol sampling technology as part of a platform for disease and environmental diagnostics. Our lead product, PBM-HALE is a passive fluid aerosol sampler engineered to segregate exhaled and environmental particles by size. Our technology solves key pains in avoiding sample contamination, preventing sample loss and generating highly reproducible data with digital molecular precision. The first of a series of products, PBM-HALE has demonstrated utility in biological agent capture, genomic/microbiomic analytics, and metabolomic profiling, through a one-stop solution. Our vision is to develop the first hand-held biomolecular analyser for medical, veterinary, well-being and environmental use. Our mission is to deliver molecular diagnostic-grade health data from your lips to your hand. PulmoBioMed Ltd. is a Northumbria University spinout company supported by the Northern Accelerator, iCURe, and InnovateUK.

ReadyGo™ is a technology company dedicated to simplifying diagnostic testing by offering devices and assays that make testing more accessible and decentralised. These devices streamline sample collection and seamlessly integrate with existing tests on the market. ReadyGo also designs assays and diagnostic tests tailored for use on both our innovative diagnostic platforms and other laboratory-based systems. Our products are well-suited for human healthcare and can also be applied in agricultural and veterinary diagnostics and in forensic settings.

Sense is transforming healthcare by redefining diagnostics. Founded in 2014, we strive to improve lives by bringing powerful tools for fast, accurate, and accessible diagnostics to all. We’re focused on creating a portfolio of unconstrained, instrument-free molecular diagnostic technologies. Our Veros™ platform introduces novel and proprietary rapid molecular amplification technology to detect a variety of deadly and costly diseases. We’re developing technologies that combine the power of laboratory tests with the simplicity and ease of use of products because we believe that if you can test anywhere, you can change everything.* *Professional use, patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

SENZO HEALTH HAS DEVELOPED A REVOLUTIONARY LATERAL FLOW TEST WHICH DELIVERS THE SAME ACCURACY AS LABORATORY-BASED PCR, WITH RESULTS AVAILABLE WITHIN 10 MINUTES, AT A FRACTION OF THE COST. This breakthrough technology is currently being applied to the world’s most prevalent diseases and infections where earlier and more prevalent diagnoses can make the biggest impact. Founded with the goal of developing PCR accurate point-of-care diagnostics for the world’s most deadly diseases, Senzo Health builds high sensitivity, low-cost, real-time testing technologies. PRICE Laboratory-based diagnostics are expensive, to the individual, the insurer, and the system. By lowering the price of modern diagnostics, we dramatically increase their use and value within healthcare. ACCURACY The Senzo Amplified Lateral Flow test is PCR-accurate. This means that for the first time we can bring testing for a range of new infections and diseases out of the laboratory and closer to the patient enabling a revolution in both diagnostics and treatments. SIMPLICITY Current diagnostics are too complex. From appointments to samples to laboratories to results. By simplifying diagnostics and bringing accurate and real-time testing to the patient, we can save money, save resources and save lives. SPEED Testing is about accurate results. The faster we can return a diagnosis, the sooner we can begin a treatment. Currently, patients and health care professionals often wait days for results. Real-time testing changes this forever, removing the gaps between consultation, testing, data and treatment. ACCESSIBILITY Accurate diagnostics today remain unevenly distributed. The only way to bring testing to patients in lower-income areas is to replace the complex central laboratory model with an affordable point-of-care diagnostics system without sacrificing accuracy.

Tagomics is a privately held company founded in 2020, with 2-10 employees. It is working to transform disease diagnosis through genetic, epigenetic, and fragmentomic features to identify disease-associated biomarkers and provide insights for disease profiling.

At TTP we work with start-ups through to big corporates, across multiple sectors, to solve challenging problems steeped in technology. By combing passion and flexibility with a deep expertise in science, engineering, and design, we help our clients unlock opportunities and make brilliant things happen. We're independent, we're free-thinkers and we're agile to the core, and for over 35 years it's helped us find better solutions faster – time and time again. We take a multidisciplinary approach, and our teams are set up around the project needs, which means we can tackle your problem holistically from the start. What's more, we'll be on your side and work with you as one team, and we'll want the project to succeed as much as you do.

Virax Biolabs is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases.

Virusight has developed an AI-powered digital Healthcare platform that enables affordable, ultra-fast diagnostic testing solutions that provide highly accurate results in less than 20 seconds. SpectraLIT®, Newsight Imaging's miniaturized Spectrophotometer device combined with Virusight's unique AI algorithm, is a revolutionary Digital Healthcare Platform for immediate medical diagnoses. (e.g, Pathogens, Urine Analysis, Early Cancer Biomarkers Detection and more) Virusight Diagnostic is a Joint Venture between Sheba‘s ARC, the medical innovation arm of Sheba Medical Center, Israel's largest hospital and Newsight Imaging, Manufacturer of SpectraLIT®.

Xgenera is dedicated to transforming cancer diagnosis through their groundbreaking multi-cancer early detection (MCED) test. With a mission to save lives by identifying cancer at its earliest stages, Xgenera leverages cutting-edge technology and advanced algorithms to detect a wide range of cancers with exceptional accuracy. By detecting cancer earlier, when treatment options are most effective, Xgenera aims to improve patient outcomes and ultimately reduce the global burden of cancer. Backed by data from large patient cohorts and ongoing research, Xgenera's MCED test holds the potential to revolutionise cancer diagnosis around the world. With a commitment to empowering individuals and healthcare providers with timely, actionable information, Xgenera is at the forefront of the fight against cancer, paving the way for a future where early detection saves lives.